Skip to main content

Table 3 Antinociceptive activities

From: Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor

 

ED 50(mg/kg, s.c.) (95% CL)

 

HP a

TF b

PPQ c

Oxycodoned

1.37 (0.48-3.92)

0.94 (0.40-2.30)

0.38 (0.19-0.75)

14-OMC

1.02 (0.52-2.01)

0.80 (0.32-2.04)

0.22 (0.12-0.41)

1 d

0.50 (0.12-2.02)

1.88 (1.25-2.83)

0.18 (0.076-0.42)

2 d

0.15 (0.054-0.41)

0.12 (0.061-0.23)

0.026 (0.012-0.055)

3 d

0.25 (0.11-0.59)

0.21 (0.11-0.40)

0.11 (0.072-0.16)

4

1.30 (0.56-3.03)

1.34 (0.53-3.03)

0.18 (0.08-0.43)

5

0.080 (0.011-0.61)

0.040 (0.020-0.090)

0.0023 (0.0009-0.0060)

6

0.089 (0.037-0.21)

0.12 (0.070-0.20)

0.003 (0.0007-0.012)

  1. Antinociceptive potencies in mice after s.c. administration shown as ED50 values with 95% confidence limits (95% CL) (n = 6–10 mice per group). aHot-plate (HP) test. bTail-flick (TF) test. cPPQ abdominal stretching test. dData from [30].
Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us